Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.
Valneva at a glance
Total revenues in 2022
Unique vaccine development programs
differentiated clinical and pre-clinical assets
robust commercial portfolio
on prevention of infectious diseases with significant unmet medical need
employees in six countries